Table 1 Characteristics of patients ≥65 years receiving the first allogeneic HCT for NHL from 2000 to 2015.

From: Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis

Variable

2000–2005 (%)

N = 76

2006–2010 (%)

N = 238

2011–2016 (%)

N = 413

P-value

Age at HCT, median (range)

67 (65–75)

67 (65–76)

68 (65–77)

0.94

Male gender

56 (74)

152 (64)

280 (68)

0.26

Race

   

0.71

Caucasian

69 (91)

219 (92)

385 (93)

 

Othersa

6 (8)

17 (7)

27 (7)

 

Karnofsky Performance Score ≥90

16 (21)

125 (53)

245 (59)

<0.001

HCT-CI

   

<0.001

0

0

72 (30)

96 (23)

 

1–2

0

42 (18)

132 (32)

 

≥3

0

61 (26)

182 (44)

 

Not available before 2007

76

58 (24)

0

 

Missing

0

5 (2)

3 (<1)

 

Histology

   

<0.001

Follicular lymphoma

9 (12)

46 (19)

61 (15)

 

Diffuse large B-cell lymphoma

15 (20)

61 (26)

144 (35)

 

Mantle cell lymphoma

29 (38)

91 (38)

94 (23)

 

Mature T-/NK-cell lymphoma

12 (16)

30 (13)

98 (24)

 

Othersb

11 (14)

10 (4)

16 (4)

 

Interval from diagnosis to HCT, months

   

0.39

Median (range)

31 (<1–207)

37 (<1–296)

33 (2–322)

 

Disease status prior to HCT

   

<0.001

Sensitive

56 (74)

192 (81)

361 (87)

 

Resistant

13 (17)

42 (18)

47 (11)

 

Untreated/unknown

7 (9)

4 (2)

5 (1)

 

History of prior autologous HCT

17 (22)

68 (29)

138 (33)

0.11

Conditioning regimens

   

0.62

Myeloablative

6 (8)

13 (5)

30 (7)

 

RIC

70 (92)

225 (95)

383 (93)

 

ATG/alemtuzumab in conditioning

25 (33)

59 (25)

105 (25)

<0.001

Graft source

   

0.74

Bone marrow

11 (14)

35 (15)

55 (13)

 

Peripheral blood

64 (84)

193 (81)

339 (82)

 

Umbilical cord blood

1 (1)

10 (4)

19 (5)

 

Donor type

   

<0.001

Matched related donor

46 (61)

87 (37)

120 (29)

 

Haploidentical donor

9 (12)

22 (9)

41 (10)

 

Matched unrelated donor

16 (21)

100 (42)

195 (47)

 

Mismatched unrelated donor

4 (5)

19 (8)

38 (9)

 

Cord blood

1 (1)

10 (4)

19 (5)

 

GVHD prophylaxis

   

<0.001

Post CY + other(s)

19 (25)

49 (20.6)

81 (19.6)

 

CNI + MTX + other(s) except MMF, PT-CY

19 (25)

72 (30.3)

151 (36.6)

 

CNI + MMF + other(s), PT-CY

16 (21.1)

75 (31.5)

117 (28.3)

 

CNI + other(s) except MMF, MTX, and PT-CY

2 (2.6)

23 (9.7)

46 (11.1)

 

CNI alone

13 (17.1)

14 (5.9)

11 (2.7)

 

Missing

7 (9.2)

5 (2.1)

7 (1.7)

 

Donor/recipient CMV status

   

<0.001

D+/R–

0

30 (13)

38 (9)

 

Others

15 (20)

162 (68)

280 (68)

 

Cord blood

1 (1)

10 (4)

19 (5)

 

Missing

60 (79)

36 (15)

76 (18)

 

Median follow-up of survivors (range), months

128 (3–168)

73 (13–120)

36 (6–65)

 
  1. HCT hematopoietic cell transplant, HCT-CI hematopoietic cell transplant comorbidity index, ATG antithymocyte globulin, D donor, R recipient, CNI calcineurin inhibitors, MTX methotrexate, MMF mycophenalate mofetil
  2. aPatient race—ther: 18 African-American; 13 Asian; 7 Hispanic or latino; 3 White NOS/American Indian; 9 patients refused to provide race/unknown
  3. bSubtype of lymphoma—Other: 7 nodal marginal zone B cells; 7 Burkitt/non-Burkitt; 4 B cells between DLBCL and Burkitt; 5 extranodal marginal zone B cells of MALT; 2 high-grade B-cell lymphomas; 3 small lymphoplasmacytic; 2 low-grade lymphoma; 7 unclassifiable
Back to article page